Floatz logo

TAMOXIFEN

Squamous Cell Carcinoma of the Head and Neck

Yung Shin Pharm. Ind. Co., Ltd.Small moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Squamous Cell Carcinoma of the Head and Neck cohort.

Asset / SponsorPhaseRating
Ipilimumab
Neonc Technologies, Inc.
Phase 2B
ln-145-s1
Iovance Biotherapeutics, Inc.
Phase 2CCC
Lifileucel
Iovance Biotherapeutics, Inc.
Phase 2CCC
Gen-009 Adjuvanted Vaccine
Genocea Biosciences, Inc.
Phase 1/2CCC
Modi-1 Moditope
Scancell Ltd
Phase 1/2CCC

View all 42 →

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →